Treating Congestive Heart Failure Using a Device to Remove Cholesterol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00510601
Recruitment Status : Completed
First Posted : August 2, 2007
Last Update Posted : January 13, 2016
Kaneka Pharma America LLC
Information provided by (Responsible Party):
Patrick Moriarty, MD, FACP, FACC, University of Kansas Medical Center

Brief Summary:

A pilot study to examine the effects of LDL-Apheresis on patients with Stage III Congestive Heart Failure.

Study hypothesis: Decreased blood viscosity from receiving LDL-apheresis will decrease workload on the heart and improve symptoms associated with the progression of Congestive Heart Failure

Condition or disease Intervention/treatment Phase
Heart Decompensation Device: Kaneka Liposorber Early Phase 1

Detailed Description:
Patients who qualify for the study will receive 7 bi-weekly LDL-Apheresis treatments with the Kaneka Liposorber device. Patients will assess their CHF symptoms using the KC Cardiomyopathy questionnaire prior to each treatment. Blood levels of certain indices related to CHF and safety profile labs will be drawn before and after the first and last treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LDL Apheresis for the Treatment of Congestive Heart Failure
Study Start Date : July 2007
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Device: Kaneka Liposorber
LDL-apheresis on a bi-weekly basis
Other Name: Liposorber LA-15 System (Kaneka, Osaka, Japan)

Primary Outcome Measures :
  1. Improved Symptoms score on KCCQ [ Time Frame: 3 Months ]
  2. Improved Ejection Fraction on ECHO [ Time Frame: 3 Months ]
  3. Improved distance during 6-minute walk test [ Time Frame: 3 Months ]

Secondary Outcome Measures :
  1. Various lab measurements measured pre and post the 1st and last treatment, including blood viscosity [ Time Frame: Approximately 2 hours, 3 months apart ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or Female, between the age of 18 and 85 years old. If female, must guarantee that pregnancy will not occur for duration of study
  • Presence of Left ventricular systolic dysfunction due to ischemic or non-ischemic cardiomyopathy and have symptoms of New York Heart Association Class III chronic Heart failure (CHF)
  • Left ventricular ejection fraction (LVEF) ≤ 35% as measured by radionuclide angiography
  • Subject must be on optimal conventional heart failure therapy including Beta-blocker in target or maximally tolerated doses for at least 3 months prior to entry into the study, and/or an angiotension receptor blocker (ARB) for at least 30 days prior to study entry. Subjects on ACE inhibitors, with approval of their physician, have been switched to an ARB one week before initiating apheresis
  • Other optimal conventional therapy have been taken for at least 30 days prior to initiation of apheresis
  • Subject is able to complete the 6-minute walk test and the Kansas City Congestive Heart Failure Quality of Life Questionnaire (KCCQ)
  • Not currently in, or planning to participate in other studies

Exclusion Criteria:

  • Age <18 years, or >85 years of age
  • Poor venous access
  • CHF due to, or associated with, uncorrected primary valvular disease, uncorrected thyroid disease, obstructive/hypertrophic cardiomyopathy, pericardial disease, amyloidosis, active myocarditis, malfunctioning artificial heart valve, uncorrected congenital heart disease, or primary pulmonary hypertension
  • Subject has undergone a cardiac revascularization, valvular surgery, or bi-ventricular resynchronization procedure within six months prior to initiation of apheresis treatment
  • Subject is listed for transplantation and is expected to be transplanted within 6 months of initiation of apheresis treatment
  • Subject has had a myocardial infarction within 6 months prior to initiation of apheresis treatment
  • Subject with electrocardiogram (ECG) recorded at initial screening showing particular abnormalities
  • Subject has sustained VT, unless precipitated by an event such as an acute myocardial infarction, induction by catheter replacement, or by an electrophysiology procedure, or addressed by placement of an automatic implantable cardiac defibrillator (AICD)
  • Subject has an AICD that has fired for any ventricular arrhythmia within 90 days of the initial visit
  • Subject has unstable angina
  • Subject on a mechanical assist device
  • Subject has evidence of concomitant disease that may interfere with the natural course of the subjects underlying heart failure for the duration of the study
  • Subject has poorly controlled diabetes mellitus
  • Subject is currently taking study prohibited medication
  • Subject is unable to tolerate Beta blocker therapy or asthma, has a heart rate of <55 bpm, or the presence of second or third degree heart block without an implanted pacemaker, and first-degree heart block with a PR interval > 220 milliseconds
  • Subject has active disease, that in the opinion of the Investigator, may adversely affect the safety and efficacy of the treatment or the life span of the patient
  • Subject has history of, or is currently abusing alcohol or illicit drugs
  • Subject has serum potassium <4.0 mEq/L or >5.5mEq/L at initial visit
  • Subject has serum digoxin level of >1.2ng/mL at time of initial visit
  • Subject is pregnant or at risk of becoming pregnant during study
  • Subject is currently lactating
  • Subject has participated in a clinical drug or device trial in the last 90 days
  • Subject has demonstrated noncompliance with previous medical regimens
  • Subject is currently hospitalized, and is not hemodynamically stable, or has an acute cardiac or non-cardiac illness that requires further hospitalization
  • Subject is unable, or unwilling to change from an ACEI to an ARB
  • Subject has a known hypersensitivity to heparin or ethylene oxide
  • Subject has a known Low-density lipoprotein cholesterol (LDL-C) level of >130mg/dl

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00510601

United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
Patrick Moriarty, MD, FACP, FACC
Kaneka Pharma America LLC
Principal Investigator: Patrick Moriarty, M.D. University of Kansas Medical Center

Responsible Party: Patrick Moriarty, MD, FACP, FACC, Director, Clinical Pharmacology, University of Kansas Medical Center Identifier: NCT00510601     History of Changes
Other Study ID Numbers: 10282
First Posted: August 2, 2007    Key Record Dates
Last Update Posted: January 13, 2016
Last Verified: January 2016

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases